NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
11/24/2023
Back to search
Official data from USPTO
BIOPHARMA CONSULTANTS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BIOPHARMA CONSULTANTS
ST13
US500000076348637Class
42
Filing
76348637
Registration
2720705
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/24/2023
Trademark type
Word
Nice classes
42
Filing date
12/13/2001
Registration date
06/03/2003
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/24/2023
Last transaction
11/24/2023
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
11/03/2001
First use in commerce
11/03/2001
Drawing code
1
Owner type
03
Owner location
CHAPEL HILL, NC, US
Examiner
PRICE, WANDA
Law office
M20
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
BIOPHARMA STRATEGIES GROUP, INC.
BioPharma Consultants, Ltd.
Representatives
Holly A. Coldiron Hutchison PLLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Consulting services relating to product development; preparation of governmental and regulatory agency filings in the fields of pharmaceuticalsbiotechnologymedical devices
Publications
History of USPTO decisions and trademark events.
29 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
11/24/2023
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
11/24/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/24/2023
E89R
TEAS SECTION 8 & 9 RECEIVED
05/30/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/22/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/22/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/22/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/13/2013
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/23/2013
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/23/2013
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/23/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/23/2013
E89R
TEAS SECTION 8 & 9 RECEIVED
02/07/2013
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
06/05/2009
PLGL
ASSIGNED TO PARALEGAL
06/03/2009
E815
TEAS SECTION 8 & 15 RECEIVED
06/01/2009
CFIT
CASE FILE IN TICRS
06/24/2008
R.PR
REGISTERED-PRINCIPAL REGISTER
06/03/2003
PUBO
PUBLISHED FOR OPPOSITION
03/11/2003
NPUB
NOTICE OF PUBLICATION
02/19/2003
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/27/2002
CNEA
EXAMINERS AMENDMENT MAILED
12/13/2002
CNFR
FINAL REFUSAL MAILED
12/10/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2002
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2002
CNRT
NON-FINAL ACTION MAILED
03/12/2002
DOCK
ASSIGNED TO EXAMINER
03/06/2002
Continuous trademark protection
Get notified about every new filing that threatens BIOPHARMA CONSULTANTS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.